

#### Date: 10 February 2025

То	То
National Stock Exchange of India Limited	BSE Limited
Exchange Plaza, C-1, Block G, Bandra Kurla	Phiroze Jeejeebhoy Towers, Dalal Street
Complex, Bandra (E), Mumbai – 400 051	Mumbai – 400001
NSE Scrip Symbol: SaiLife	BSE Scrip Code: 544306

# Sub: Monitoring Agency Report for the quarter ended 31 December 2024 in relation to the Initial Public Offer (IPO) of the Company.

Dear Sir/ Madam,

Pursuant to Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find attached Monitoring Agency Report for the quarter ended 31 December 2024 issued by CRISIL Ratings Limited, Monitoring Agency, appointed to monitor the utilisation of proceeds of the IPO of the Company.

We request you to take note of the same and oblige.

Thank you.

For Sai Life Sciences Limited

Runa Karan Company Secretary & Compliance Officer Membership No.: A13721

Encl: As above

#### Sai Life Sciences Limited

CIN: U24110TG1999PLC030970

Registered Office: Plot No.DS-7, IKP Knowledge Park, Turkapally (V), Shameerpet Mandal, Medchal-Malkajgiri Dist-500078, Telangana, India. T: +91 40 6815 6000, F: +91 40 6815 6199

E: <u>info@sailife.com</u> www.sailife.com Corporate Office:

# L4-01&02, SLN Terminus, Survey #133, Gachibowli Miyapur Road, Gachibowli, Hyderabad-500032, Telangana, India.



# Monitoring Agency Report for Sai Life Sciences Limited for the quarter ended December 31, 2024





## CRL/MAR/SALSCL/2024-25/1283

February 08, 2025

То

**Sai Life Sciences Limited** Plot No. DS- 7, IKP Knowledge Park, Turkapally Village, Shameerpet Mandal, Medchal – Malkajgiri District, Hyderabad 500 078, Telangana, India

Dear Sir,

# Monitoring Agency Report for the quarter ended December 31, 2024 - in relation to the Initial Public Offer ("IPO") of Sai Life Sciences Limited ("the Company")

Pursuant to Regulation 41(2) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations") and Monitoring Agency Agreement dated December 05, 2024, enclosed herewith the Monitoring Agency Report, issued by Crisil Ratings Limited, Monitoring Agency, as per Schedule XI of the SEBI ICDR Regulations towards utilization of proceeds of IPO for the quarter ended December 31, 2024.

Request you to kindly take the same on records.

Thanking you, For and on behalf of Crisil Ratings Limited

Sushant Sarode Director, Ratings (LCG)



# Crisil Ratings

# Report of the Monitoring Agency (MA)

Name of the issuer: Sai Life Sciences Limited

For quarter ended: December 31, 2024

Name of the Monitoring Agency: Crisil Ratings Limited

(a) Deviation from the objects: Not applicable

(b) Range of Deviation: Not applicable

# Declaration:


We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013.

The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit-related analyses. We confirm that we do not perceive any conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer.

We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title "Comments of the Board of Directors", that shall be captured by the Issuer's Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer's Management/Board.

Signature:

Name and designation of the Authorized Signatory: Sushant Sarode Designation of Authorized person/Signing Authority: Director, Ratings (LCG)



#### 1) Issuer Details:

Name of the issuer:	Sai Life Sciences Limited
Names of the promoter:	Mr. Ranga Raju Kanumuri Mr. Mytreyi Kanumuri Sai Quest Syn Private Limited Mr. Krishnam Raju Kanumuri Mytreyi Kanumuri (Partner of Marigold Partners) Mytreyi Kanumuri (Partner of Tulip Partners) Ranga Raju Kanumuri (Partner of Sunflower Partners) Ranga Raju Kanumuri (Partner of Lily Partners)
Industry/sector to which it belongs:	Healthcare Research, Analytics & Technology
2) Issue Details	
Issue Period:	December 11, 2024, to December 13, 2024
Type of issue (public/rights):	Initial Public Offer (IPO)
Type of specified securities:	Equity Shares
IPO Grading, if any:	NA
Issue size:	Rs 30,426.20 million (Fresh issue of Rs 9,500.00 million and OFS of Rs 20,926.20 million)

#### \*Note:

Particulars	Amount (Rs. In million)
Gross proceeds of the Fresh Issue	9,500.00#
Less: Issue Expenses	401.16 <sup>\$</sup>
Net Proceeds	9,098.84

*CRISIL Ratings shall be monitoring the gross proceeds.* 

<sup>\$</sup>Out of the issue expenses of Rs 401.16 million, the Company has spent Rs 45.57 million towards the issue expenses as at the quarter ended December 31, 2024, and the remaining Rs 355.59 million are parked in fixed deposits and public offer account of the Company.

The above disclosure is based on management undertaking and Certificate dated January 30, 2025, issued by M/s Bashetty & Joshi, Chartered Accountants (Firm Registration Number: 013299S), Peer-reviewed Independent Chartered Accountants.

# Crisil Ratings

3) Details of the arrangement made to ensure the monitoring of issue proceeds:

Particulars	Reply	Source of information/ certifications considered by Monitoring Agency for preparation of report	Comments of the Monitoring Agency	Comments of the Board of Directors
Whether all utilization is as per the disclosures in the Offer Document?	Yes	Management undertaking, Peer- reviewed Independent Chartered Accountant certificate^, Prospectus, Bank Statements	No Comments	No Comments
Whether shareholder approval has been obtained in case of material deviations from expenditures disclosed in the Offer Document?	NA		No Comments	No Comments
Whether the means of finance for the disclosed objects of the issue has changed?	No		No Comments	No Comments
Is there any major deviation observed over the earlier monitoring agency reports?	No		No Comments	No Comments
Whether all Government/statutory approvals related to the object(s) have been obtained?	NA	Management undertaking, Peer- reviewed Independent	No Comments	No Comments
Whether all arrangements pertaining to technical assistance/collaboration are in operation?	NA	Chartered Accountant certificate^	No Comments	No Comments
Are there any favorable events improving the viability of these object(s)?	NA		No Comments	No Comments
Are there any unfavorable events affecting the viability of the object(s)?	NA		No Comments	No Comments
Is there any other relevant information that may materially affect the decision making of the investors?	NA		No Comments	No Comments

NA represents Not Applicable

<sup>^</sup>Certificate dated January 30, 2025, issued by M/s Bashetty & Joshi, Chartered Accountants (Firm Registration Number: 013299S), Peer-reviewed Independent Chartered Accountants.



# 4) Details of object(s) to be monitored:

# i. Cost of the object(s):

		Source of	Original			Commen	ts of the Boar	rd of Directors
Sr. No.	Item Head	information/ certification considered by MA for preparation of report	cost (as per the Offer Document) (Rs in million)	Revised Cost (Rs in million)	Comment of the Monitorin g Agency	Reason of Cost revision	Proposed financing option	Particulars of firm arrangements made
1	Repayment/prepayment, in full or part, of all or certain outstanding borrowings availed by the Company	Management undertaking, Peer-reviewed Independent Chartered Accountant certificate^, Prospectus	7,200.00	NA	No revision		No Comme	ents
2	General corporate purposes		1,898.84	NA	No revision		No Comme	ents
	Total		9,098.84	-	-	-	-	-

^Certificate dated January 30, 2025, issued by M/s Bashetty & Joshi, Chartered Accountants (Firm Registration Number: 013299S), Peerreviewed Independent Chartered Accountants.

*#The amount utilised for general corporate purposes does not exceed 25% of the Gross Proceeds (amounting to Rs 2,375.00 million) from the Fresh Issue.* 






## ii. Progress in the object(s):

		Source of information/	Amount utilized (Rs in million)					Comments of the Board of Directors				
Sr. No.	Item Head#	certifications a considered by prop Monitoring in Agency for Of preparation of report (Re mill		em Head# considered by J Monitoring Agency for preparation of L report		As at beginnin g of the quarter	During the quarter	At the end of the quarter	Total unutilized amount (Rs in million)	Comments of the Monitoring Agency	Reasons for idle funds	Proposed course of action
1	Repayment/ prepayment, in full or part, of all or certain outstanding borrowings availed by the Company	undertaking, Peer-	7 <i>,</i> 200.00	Nil	5,857.25	5,857.25	1,342.75	Proceeds utilized as per the details mentioned in the Prospectus	No Co	mments		
2	General corporate purposes	Sutchents	1,898.84	Nil	50.62	50.62	1,848.22	Refer note	No Co	mments		
	Total		9,098.84	Nil	5,907.87	5,907.87	3,190.97	-	-	-		

<sup>^</sup>Certificate dated January 30, 2025, issued by M/s Bashetty & Joshi, Chartered Accountants (Firm Registration Number: 013299S), Peerreviewed Independent Chartered Accountants.

Note:

*Rs* 50.62 *million were transferred from Monitoring account of the Company to its other cash credit accounts for utilization towards general corporate purposes, for operational ease. The transferred proceeds stands fully utilized as at the quarter ended December 31, 2024.* 





# **\*Brief description of objects:**

Object of the Issue	Description of objects as per the offer document filed by the issuer
Repayment/ prepayment, in full or part, of all or certain outstanding borrowings availed by the Company	The Company proposes to utilise an estimated amount of Rs. 7,200.00 million from the Net Proceeds towards repayment/ prepayment, in part or full, of all or a portion of certain borrowings availed by the Company.
General corporate purposes	<ul> <li>General corporate purposes may include, but are not restricted to,</li> <li>(i) strategic initiatives,</li> <li>(ii) funding growth opportunities, expansion initiatives and meeting exigencies,</li> <li>(iii) brand building,</li> <li>(iv) purchase of equipment and machinery,</li> <li>(v) meeting expenses incurred by the Company in the ordinary course of business, and</li> <li>(vi) any other purpose as may be approved by the Board or duly appointed committee, from time to time, subject to compliance with Companies Act, 2013 and all other applicable laws.</li> <li>The quantum of utilisation of funds towards each of the above purposes will be determined by the Board of Directors of the Company, based on the amount available under this head and business requirements, from time to time.</li> </ul>




# iii. Deployment of unutilised proceeds^:

S. No.	Type of instrument where amount is invested	Amount invested (in Rs million)	Maturity date	Earnings as on December 31, 2024 (in Rs million)	Return on Investment (%)	Market value as at the end of quarter (in Rs million)
1	ICICI Bank - Fixed Deposits - 000810117320	165.87	02-Jan-25	0.11	4.75%	165.98
2	DBS Bank - Fixed Deposits - 8856241219012102	642.75	03-Jan-25	1.38	6.52%	644.13
3	DBS Bank - Fixed Deposits - 8856241219012096	700.00	03-Jan-25	1.50	6.52%	701.50
4	SBI Bank - Fixed Deposits - 43640486875	250.00	20-Dec-25	0.58	7.70%	250.58
5	SBI Bank - Fixed Deposits - 43640490609	250.00	20-Dec-25	0.58	7.70%	250.58
6	SBI Bank - Fixed Deposits - 43640573246	250.00	20-Dec-25	0.58	7.70%	250.58
7	SBI Bank - Fixed Deposits - 43640574336	250.00	20-Dec-25	0.58	7.70%	250.58
8	SBI Bank - Fixed Deposits - 43640575878	250.00	20-Dec-25	0.58	7.70%	250.58
9	SBI Bank - Fixed Deposits - 43640576939	250.00	20-Dec-25	0.58	7.70%	250.58
10	SBI Bank - Fixed Deposits - 43640525271	200.00	20-Dec-25	0.46	7.65%	200.46
11	IndusInd Bank - Fixed Deposits - 301029744586	103.81	31-Dec-25	-	7.90%	103.81
12	Balance in Public Offer Account - 924020069487933#	234.13	-	-	-	234.13
	Total	3,546.56*		6.93		3,553.49

*^On the basis of management undertaking & Certificate dated January 30, 2025, issued by M/s Bashetty & Joshi, Chartered Accountants (Firm Registration Number: 013299S), Peer-reviewed Independent Chartered Accountants.* 

\*Out of Rs 3,546.56 million, Rs 3,190.97 million pertains to net proceeds and Rs 355.59 million pertains to issue expenses.





# iv. Delay in implementation of the object(s):


	Completion Date		Delay	Comments of the Board of Directors	
00)(((3)	As per the Offer Document	Actual	(no. of days/	Reason of delay	Proposed course of action
Not applicable^					

*^On the basis of management undertaking & Certificate dated January 30, 2025, issued by M/s Bashetty & Joshi, Chartered Accountants (Firm Registration Number: 013299S), Peer-reviewed Independent Chartered Accountants.* 

# 5) Details of utilization of proceeds stated as General Corporate Purpose^ amount in the offer document:

S. No.	Item heads	Amount (Rs in million)	Remarks
1	Purchase of Equipment and Machinery	21.81	Capital expenditure
2	Meeting the expenses incurred by the Company in the ordinary course of business	28.81	Purchase of raw material, working capital requirements, general administrative expenses, like logistics, spares, misc.
-	Total	50.62	The funds utilised towards GCP are approved by the Board of Directors of the Company vide resolution dated February 06, 2025

*^On the basis of management undertaking & Certificate dated January 30, 2025, issued by M/s Bashetty & Joshi, Chartered Accountants (Firm Registration Number: 013299S), Peer-reviewed Independent Chartered Accountants.* 





## **Disclaimers:**

- a) This Report is prepared by Crisil Ratings Limited (hereinafter referred to as "Monitoring Agency" / "MA" / "CRL"). The MA has taken utmost care to ensure accuracy and objectivity while developing this Report based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever.
- b) This Report has to be seen in its entirety; the selective review of portions of the Report may lead to inaccurate assessments. For the purpose of this Report, MA has relied upon the information provided by the management /officials/ consultants of the Issuer and third-party sources like Peer-reviewed Independent Chartered Accountants (or from peer reviewed CA firms) appointed by the Issuer believed by it to be accurate and reliable.
- c) Nothing contained in this Report is capable or intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The MA is also not responsible for any errors in transmission and specifically states that it, or its directors, employees do not have any financial liabilities whatsoever to the users of this Report.
- d) The MA and its affiliates do not act as a fiduciary. The MA and its affiliates also do not act as an expert to the extent defined under Section 2(38) of the Companies Act, 2013. While the MA has obtained information from sources it believes to be reliable, it does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives from auditors (or from peer reviewed CA firms), lawyers, chartered engineers or other experts, and relies on in its reports.
- e) The MA or its affiliates may have other commercial transactions with the entity to which the report pertains. As an example, the MA may rate the issuer or any debt instruments / facilities issued or proposed to be issued by the issuer that is subject matter of this report. The MA may receive separate compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors.
- f) The MA report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRL providing or intending to provide any services in jurisdictions outside India, where it does not have the necessary licenses and/or registration to carry out its business activities referred to above.
- g) Access or use of this report does not create a client relationship between CRL and the user.
- *h)* CRL is not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing this report, MA has not taken into consideration the objectives or particular needs of any particular user.
- *i)* It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be a basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).
- *j)* The report comprises professional opinion of CRL as of the date they are expressed, based on the information received from the issuer and other sources considered reliable by CRL. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. The report does not constitute statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions.
- k) Neither CRL nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents guarantee the accuracy, completeness or adequacy of the report, and shall not have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. CRL and each aforesaid party disclaims any and all express or implied warranties, including but not limited to any warranties of merchantability, suitability or fitness for a particular purpose or use or use. In no event shall CRL or any aforesaid party be liable to any user for any direct, indirect, incidental, exemplary, compensatory,



punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

- *l)* CRL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with the preparation of this report. CRL has in place a code of conduct and policies for managing conflict of interest.
- *m)* Unless required under any applicable law, this report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRL.
- *n)* By accepting a copy of this Report, the recipient accepts the terms of this Disclaimer, which forms an integral part of this Report.

